- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for ImmunoGen Inc (IMGN)
| Open: | - | Day's Range: | - | Volume: | 587,599 |
|---|---|---|---|---|---|
| Previous Close: | 16.2900 | 52wk Range: | 10.8500 - 18.1000 | 1-Yr Rtn: | +20.58% |
Key Statistics for IMGN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(06/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.9000 |
| Est. EPS (USD) (06/2013) | -0.9450 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 1,377.06 |
| Shares Outstanding (M) | 84.53 |
| 30 Day Average Volume | 832,470 |
| Price/Book (mrq) | 9.8954 |
| Price/Sale (ttm) | 39.2624 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for IMGN
Company Profile & Key Executives for IMGN
ImmunoGen, Inc. develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology together with its expertise in monoclonal antibodies and tumor biology. A TAP compound uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's purpose-developed cancer-killing agents specifically to tumor cells.
| DANIEL M JUNIUS "Dan"President/CEO | Gregory D Perry "Greg"Exec VP/CFO/Treasurer |
| Charles Morris "Charlie"Exec VP/Chief Development Ofcr | James J O'LearyVP/Chief Medical Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
IMGN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page